Evidence map›Paper›PMID 25400428›Full record

ReviewChinese journal of cancer research = Chung-kuo yen cheng yen chiu2014

Alpha-2-macroglobulin as a radioprotective agent: a review.

Xueying Chen, Xiangbo Kong, Zhaoqiang Zhang, Wei Chen, Jieyu Chen, Huanyang Li, Wanting Cao, Yaping Ge, Silian Fang

Open access · greenAbstract readReview
In one paragraph

Review in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xueying Chen1 Department of Oral and Maxillofacial Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China ; 2 Department of Periodontology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China ; 3 Department of Stomatology, Zhuhai Hospital, Guangdong Provincial Hospital of Traditional Chinese Medical, Zhuhai 519015, China.
Xiangbo Kong1 Department of Oral and Maxillofacial Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China ; 2 Department of Periodontology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China ; 3 Department of Stomatology, Zhuhai Hospital, Guangdong Provincial Hospital of Traditional Chinese Medical, Zhuhai 519015, China.
Zhaoqiang Zhang1 Department of Oral and Maxillofacial Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China ; 2 Department of Periodontology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China ; 3 Department of Stomatology, Zhuhai Hospital, Guangdong Provincial Hospital of Traditional Chinese Medical, Zhuhai 519015, China.
Wei Chen1 Department of Oral and Maxillofacial Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China ; 2 Department of Periodontology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China ; 3 Department of Stomatology, Zhuhai Hospital, Guangdong Provincial Hospital of Traditional Chinese Medical, Zhuhai 519015, China.
Jieyu Chen1 Department of Oral and Maxillofacial Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China ; 2 Department of Periodontology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China ; 3 Department of Stomatology, Zhuhai Hospital, Guangdong Provincial Hospital of Traditional Chinese Medical, Zhuhai 519015, China.
Huanyang Li1 Department of Oral and Maxillofacial Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China ; 2 Department of Periodontology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China ; 3 Department of Stomatology, Zhuhai Hospital, Guangdong Provincial Hospital of Traditional Chinese Medical, Zhuhai 519015, China.
Wanting Cao1 Department of Oral and Maxillofacial Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China ; 2 Department of Periodontology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China ; 3 Department of Stomatology, Zhuhai Hospital, Guangdong Provincial Hospital of Traditional Chinese Medical, Zhuhai 519015, China.
Yaping Ge1 Department of Oral and Maxillofacial Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China ; 2 Department of Periodontology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China ; 3 Department of Stomatology, Zhuhai Hospital, Guangdong Provincial Hospital of Traditional Chinese Medical, Zhuhai 519015, China.
Silian Fang1 Department of Oral and Maxillofacial Surgery, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China ; 2 Department of Periodontology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China ; 3 Department of Stomatology, Zhuhai Hospital, Guangdong Provincial Hospital of Traditional Chinese Medical, Zhuhai 519015, China.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation is an important modality in cancer treatment, and eighty percent of cancer patients need radiotherapy at some point during their clinical management. However, radiation-induced damage to normal tissues restricts the therapeutic doses of radiation that can be delivered to tumours and thereby limits the effectiveness of the treatment. The use of radioprotectors represents an obvious strategy to obtain better tumour control using a higher dose in radiotherapy. However, most of the synthetic radioprotective compounds studied have shown inadequate clinical efficacy owing to their inherent toxicity and high cost. Hence, the development of radioprotective agents with lower toxicity and an extended window of protection has attracted a great deal of attention, and the identification of alternative agents that are less toxic and highly effective is an absolute necessity. Recent studies have shown that alpha-2-macroglobulin (α2M) possesses radioprotective effects. α2M is a tetrameric, disulfide-rich plasma glycoprotein that functions as a non-selective inhibitor of different types of non-specific proteases and as a carrier of cytokines, growth factors, and hormones. α2M induces protein factors whose interplay underlies radioprotection, which supports the idea that α2M is the central effector of natural radioprotection in the rat. Pretreatment with α2M has also induced a significant reduction of irradiation-induced DNA damage and the complete restoration of liver and body weight. Mihailović et al. concluded that the radioprotection provided by α2M was in part mediated through cytoprotection of new blood cells produced in the bone marrow; these authors also indicated that an important aspect of the radioprotective effect of amifostine was the result of the induction of the endogenous cytoprotective capability of α2M. The radioprotective effects of α2M are possibly due to antioxidant, anti-fibrosis, and anti-inflammatory functions, as well as the maintenance of homeostasis, and enhancement of the DNA repair and cell recovery processes. This review is the first to summarise the observations and elucidate the possible mechanisms responsible for the beneficial effects of α2M. The lacunae in the existing knowledge and directions for future research are also addressed.

Indexed as

Alpha-2-macroglobulin (α2M)ionising radiationmechanismradiation-induced fibrosisradioprotection

Identifiers

PMID25400428
PMCPMC4220256
OpenAlexW118658937

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.